CURATE.AI - AI-derived personalized tacrolimus dosing for pediatric liver transplant: A retrospective study
Tan, S.-B.; Kumar, K. S.; Gan, T. R. X.; Truong, A. T. L.; Tan, L. W. J.; Blasiak, A.; Mali, V. P.; Aw, M. M.; Ho, D.
Show abstract
Tacrolimus is the cornerstone of immunosuppressive therapy after pediatric liver transplantation. However, reliance on the physicians experience for dose titration, coupled with tacrolimuss narrow therapeutic window and inter and intra-patient variability, often results in frequent under or over-dosing with detrimental patient outcomes. Existing predictive dose personalization models are not readily feasible for clinical implementation, as they require multiple measurements each day while the standard frequency is once daily. We developed CURATE.AI, a small-data artificial intelligence-derived platform, as a clinical decision support system to personalize doses using the patients own data obtained once a day. Retrospective dose personalization with CURATE.AI on 16 patients data demonstrated potential to enable patients to stay in the therapeutic range longer and reach the therapeutic range significantly earlier. Our findings support the testing of CURATE.AI in a prospective controlled trial as an aid for the physicians decision on tacrolimus dose personalization after pediatric liver transplantation.
Matching journals
The top 5 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Model-informed Deep Q-Networks to Guide Infliximab Dosing in Pediatric Crohn's Disease 92%
- Pathway-based similarity measurement to quantify transcriptomics similarity between human tissues and preclinical models. 92%
- MTXPK.org: A clinical decision support tool evaluating high-dose methotrexate pharmacokinetics to inform post-infusion care and use of glucarpidase 91%
Similar papers in this journal
- A Strategy to Treat COVID-19 Disease with Targeted Delivery of Inhalable Liposomal Hydroxychloroquine: A Non-clinical Pharmacokinetic Study 90%
- In silico PK predictions in Drug Discovery: Benchmarking of Strategies to Integrate Machine Learning with Empiric and Mechanistic PK modelling 89%
- A Framework to Quantify Disparities in Pharmacogenomic Treatment Concordance and Drug Response Outcomes 89%
Similar papers in this journal
- Bridging the gap between in silico and in vivo: modeling opioid disposition in a kidney proximal tubule microphysiological system 91%
- Application of physiological network mapping in the prediction of survival in critically ill patients with acute liver failure 89%
- The molecular basis of the anticancer effect of statins 89%
Similar papers in this journal
Similar papers in this journal
- PBPK modelling of dexamethasone in patients with COVID-19 and liver disease 92%
- Predicting transdermal fentanyl delivery using mechanistic simulations for tailored therapy 89%
- Sex-associated differences in cytomegalovirus prevention: Prophylactic strategy is associated with a strong kidney function impairment in female renal transplant patients 89%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.